Status:
RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Lead Sponsor:
Monash University
Conditions:
Myeloma
Non Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. ...
Detailed Description
This is a domain within the RATIONAL Platform Trial to test the effectiveness and safety of prophylactic antibiotics as an alternative Ig replacement in patients who have not yet commenced Ig replacem...
Eligibility Criteria
Inclusion
- Patients must be receiving IVIg replacement at standard dose for prevention of bacterial infections due to hypogammaglobulinaemia for at least 6 consecutive months.
- Patient is not eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.
Exclusion
- Prior or planned allogeneic haematopoietic stem cell transplantation.
- Major infection (Grade 3 or higher) in preceding 3 months, and or current active infection requiring systemic antimicrobial treatment.
- Previous splenectomy.
- Known history of bronchiectasis.
- Previous participation in this domain.
- Treating team deems enrolment in the domain is not in the best interest of the patient.
Key Trial Info
Start Date :
April 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2027
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT07202065
Start Date
April 28 2025
End Date
March 31 2027
Last Update
October 7 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
2
Austin Hospital
Melbourne, Victoria, Australia, 3004
3
Northern Health
Melbourne, Victoria, Australia, 3004